Condition: Pulmonary Arterial Hypertension · Sponsor: Actelion
The Opsumit Users registry (OPUS; NCT02126943) was developed to characterize the safety profile of Opsumit and to describe clinical characteristics and outcomes of patients newly treated with Opsumit in the post-marketing setting. It is expected that the recruitment target of the OPUS registry cannot be achieved within the planned time period (5000 Opsumit new users by October 2018). The OrPHeUS study is designed to supplement the OPUS registry with retrospectively identified first-time Opsumit users in order to achieve the desired sample size.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Pulmonary Associates | Phoenix, Arizona, United States | — |
| Cardiovascular Consultants | Phoenix, Arizona, United States | — |
| Mayo Clinic - Arizona | Phoenix, Arizona, United States | — |
| University of California San Diego | La Jolla, California, United States | — |
| Loma Linda University Medical Center | Loma Linda, California, United States | — |
| University of Southern California | Los Angeles, California, United States | — |
| David Geffen School of Medicine at University of California Los Angeles | Los Angeles, California, United States | — |
| UCSF School of Medicine | San Francisco, California, United States | — |
| Paloma Medical Group | San Juan Capistrano, California, United States | — |
| Santa Barbara Cottage Hospital | Santa Barbara, California, United States | — |
| University of Colorado | Aurora, Colorado, United States | — |
| National Jewish Health | Denver, Colorado, United States | — |
+ 94 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.